Jpmorgan Chase & CO Moleculin Biotech, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.41 - $0.86 $6 - $13	16 Added 44.44%	52 $0
Q3 2023 Nov 14, 2023	BUY	$0.38 - $0.72 $13 - $25	36 New	36 $0
Q2 2022 Aug 11, 2022	SELL	$1.19 - $2.0 $706 - $1,188	-594 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.23 - $1.9 $730 - $1,128	594 New	594 $1,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $124M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.